Literature DB >> 22832224

A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924.

Julia I Toth1, Li Yang, Russell Dahl, Matthew D Petroski.   

Abstract

Inhibition of NEDD8-activating enzyme (NAE) has emerged as a highly promising approach to treat cancer through the adenosine sulfamate analog MLN4924. Here, we show that selective pressure results in HCT116 colorectal carcinoma cells with decreased MLN4924 sensitivity and identify a single-nucleotide transition that changes alanine 171 to threonine (A171T) of the NAE subunit UBA3. This reduces the enzyme's affinity for MLN4924 and ATP while increasing NEDD8 activation at physiological ATP concentrations. Expression of UBA3 A171T is sufficient to decrease MLN4924 sensitivity of naive HCT116 cells, indicating that it is a dominant suppressor of MLN4924-mediated cell death. Our data suggest that the on-target potency of MLN4924 selects for a point mutation in NAE that overcomes the molecule's inhibitory effects, allowing cancer cell survival.
Copyright © 2012 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22832224      PMCID: PMC4120840          DOI: 10.1016/j.celrep.2012.02.006

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  42 in total

1.  The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1.

Authors:  Helen Walden; Michael S Podgorski; Danny T Huang; David W Miller; Rebecca J Howard; Daniel L Minor; James M Holton; Brenda A Schulman
Journal:  Mol Cell       Date:  2003-12       Impact factor: 17.970

2.  On the origin of cancer cells.

Authors:  O WARBURG
Journal:  Science       Date:  1956-02-24       Impact factor: 47.728

3.  Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

Authors:  Daphne W Bell; Ira Gore; Ross A Okimoto; Nadia Godin-Heymann; Raffaella Sordella; Roseann Mulloy; Sreenath V Sharma; Brian W Brannigan; Gayatry Mohapatra; Jeff Settleman; Daniel A Haber
Journal:  Nat Genet       Date:  2005-10-30       Impact factor: 38.330

4.  Structural insights into E1-catalyzed ubiquitin activation and transfer to conjugating enzymes.

Authors:  Imsang Lee; Hermann Schindelin
Journal:  Cell       Date:  2008-07-25       Impact factor: 41.582

5.  Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover.

Authors:  Michael A Milhollen; Usha Narayanan; Teresa A Soucy; Petter O Veiby; Peter G Smith; Benjamin Amidon
Journal:  Cancer Res       Date:  2011-04-12       Impact factor: 12.701

6.  Nedd8 modification of cul-1 activates SCF(beta(TrCP))-dependent ubiquitination of IkappaBalpha.

Authors:  M A Read; J E Brownell; T B Gladysheva; M Hottelet; L A Parent; M B Coggins; J W Pierce; V N Podust; R S Luo; V Chau; V J Palombella
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

Review 7.  Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy.

Authors:  Robert C Kane; Peter F Bross; Ann T Farrell; Richard Pazdur
Journal:  Oncologist       Date:  2003

8.  An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer.

Authors:  Teresa A Soucy; Peter G Smith; Michael A Milhollen; Allison J Berger; James M Gavin; Sharmila Adhikari; James E Brownell; Kristine E Burke; David P Cardin; Stephen Critchley; Courtney A Cullis; Amanda Doucette; James J Garnsey; Jeffrey L Gaulin; Rachel E Gershman; Anna R Lublinsky; Alice McDonald; Hirotake Mizutani; Usha Narayanan; Edward J Olhava; Stephane Peluso; Mansoureh Rezaei; Michael D Sintchak; Tina Talreja; Michael P Thomas; Tary Traore; Stepan Vyskocil; Gabriel S Weatherhead; Jie Yu; Julie Zhang; Lawrence R Dick; Christopher F Claiborne; Mark Rolfe; Joseph B Bolen; Steven P Langston
Journal:  Nature       Date:  2009-04-09       Impact factor: 49.962

Review 9.  Cytochrome p450 and chemical toxicology.

Authors:  F Peter Guengerich
Journal:  Chem Res Toxicol       Date:  2007-12-06       Impact factor: 3.739

Review 10.  The ubiquitin system, disease, and drug discovery.

Authors:  Matthew D Petroski
Journal:  BMC Biochem       Date:  2008-10-21       Impact factor: 4.059

View more
  23 in total

Review 1.  SCF ubiquitin ligase-targeted therapies.

Authors:  Jeffrey R Skaar; Julia K Pagan; Michele Pagano
Journal:  Nat Rev Drug Discov       Date:  2014-11-14       Impact factor: 84.694

Review 2.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

3.  The cyclomodulin cycle inhibiting factor (CIF) alters cullin neddylation dynamics.

Authors:  Tasha B Toro; Julia I Toth; Matthew D Petroski
Journal:  J Biol Chem       Date:  2013-04-15       Impact factor: 5.157

Review 4.  Targeting Neddylation pathways to inactivate cullin-RING ligases for anticancer therapy.

Authors:  Yongchao Zhao; Meredith A Morgan; Yi Sun
Journal:  Antioxid Redox Signal       Date:  2014-02-20       Impact factor: 8.401

5.  Radiosensitization of Cancer Cells by Inactivation of Cullin-RING E3 Ubiquitin Ligases.

Authors:  Dongping Wei; Meredith A Morgan; Yi Sun
Journal:  Transl Oncol       Date:  2012-10-01       Impact factor: 4.243

Review 6.  Cullin-RING Ligases as attractive anti-cancer targets.

Authors:  Yongchao Zhao; Yi Sun
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

Review 7.  Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application.

Authors:  Yongchao Zhao; Yi Sun
Journal:  Neoplasia       Date:  2012-05       Impact factor: 5.715

Review 8.  Protein neddylation and its alterations in human cancers for targeted therapy.

Authors:  Lisha Zhou; Wenjuan Zhang; Yi Sun; Lijun Jia
Journal:  Cell Signal       Date:  2018-01-10       Impact factor: 4.315

Review 9.  [Targeting Cullin-RING E3 ligases for anti-cancer therapy: efforts on drug discovery].

Authors:  Qing Yu; Xiufang Xiong; Yi Sun
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2020-05-25

10.  Small molecules targeting the NEDD8·NAE protein-protein interaction.

Authors:  Chen-Ming Lin; Zhengyang Jiang; Zhe Gao; Maritess Arancillo; Kevin Burgess
Journal:  Chem Sci       Date:  2020-12-14       Impact factor: 9.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.